Impact of Live Biotherapeutic Products on Gut Microbiome in Recurrent C difficile Infections
Presented at DDW 2024 by Ken Blount, the effectiveness of live biotherapeutic products in treating recurrent C difficile infections (rCDI), offers insights into microbiota alteration and prospects for management.
Ken Blount, VP Microbiome Research, Ferring.
Understanding Clostridioides difficile Infections and Antibiotic Stewardship
In a 17-year study across 2 Québec hospitals, researchers explored the relationship between antibiotic use and healthcare-associated C difficile infections.
C Diff Therapy Demonstrates Long-Term Protection After Antimicrobial Usage
In a small study, rCDI therapy, Rebyota, was durable in a majority of patients who were exposed to non-CDI antibiotics.
Doctors typically wear protective suites when caring for patients with Clostridioides difficile infection to prevent transmission of the bacteria.
Image credits: Unsplash
Efficacy of Fecal Microbiota Transplantation for Initial C difficile Infection
Researchers assess the efficacy of fecal microbiota transplantation (FMT) for first or second episodes of C difficile infection (CDI), demonstrating high initial cure rates and sustained in managing the condition.
Navigating Dual Infections: Managing Helicobacter pylori and C difficile
A case study of an 80-year-old patient, illustrating successful management of dual H pylori and C diff infections with quadruple therapy, with key insights from Yazan Abboud, MD and Sima Vossough-Teehan, MD.
Helicobacter pylori causes stomach inflammation and peptic ulcers, while C difficile leads to severe diarrhea and colitis, often exacerbated by antibiotic use, both serious gastrointestinal issues.
Image credits: Unsplash
Reducing Unnecessary C diff Tests Aids in Diagnostic Stewardship, Overtreatment
A Florida hospital takes a novel approach to healthcare-associated infection and reduces inappropriate testing by setting up guidelines.
